Author: Sachdeva, Muskaan; Mufti, Asfandyar; Maliyar, Khalad; Lytvyn, Yuliya; Yeung, Jensen
Title: Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment Cord-id: 5gorynd2 Document date: 2020_5_19
ID: 5gorynd2
Snippet: Abstract: Background While evidence suggests that hydroxychloroquine (HCQ) may decrease the viral load in patients with a COVID-19 infection, a number of case reports indicate adverse dermatologic effects of this potential treatment. Objective To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment. Methods A comprehensive EMBASE and MEDLINE search of original studies examining adverse effects of HCQ treatment related to psoria
Document: Abstract: Background While evidence suggests that hydroxychloroquine (HCQ) may decrease the viral load in patients with a COVID-19 infection, a number of case reports indicate adverse dermatologic effects of this potential treatment. Objective To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment. Methods A comprehensive EMBASE and MEDLINE search of original studies examining adverse effects of HCQ treatment related to psoriasis was conducted. Participant demographics, and details of HCQ administration and psoriasis diagnosis were extracted from 15 articles representing 18 patients. Results Females accounted for a significantly larger number of psoriatic cases compared to males and unreported sex (n=14, 77.8% vs. n=2, 11.1% vs n=2, 11.1% respectively). Additionally, 50% (n=9) of the cases did not have a history of psoriasis prior to taking HCQ. Of the 18 patients, 50.0% (n=9) experienced de novo psoriasis, 27.8% (n=5) experienced exacerbation of psoriatic symptoms and 22.2% (n=4) had a relapse of psoriasis after HCQ administration. Conclusions HCQ treatment may result in induction, exacerbation, or relapse of psoriasis. Monitoring for adverse effects of HCQ treatment is necessary, and clinical trials are essential in characterizing the safety profile of HCQ use in patients with a COVID-19 infection.
Search related documents:
Co phrase search for related documents- abstract title and lupus erythematosus: 1
Co phrase search for related documents, hyperlinks ordered by date